Attached files

file filename
EX-32.1 - CERTIFICATION - PDL BIOPHARMA, INC.pdli-2018033110qex321.htm
EX-31.2 - CERTIFICATION - PDL BIOPHARMA, INC.pdli-2018033110qex312.htm
EX-31.1 - CERTIFICATION - PDL BIOPHARMA, INC.pdli-2018033110qex311.htm
10-Q - 10-Q - PDL BIOPHARMA, INC.pdli-2018033110qdoc.htm


Exhibit 12.1

PDL BIOPHARMA, INC.
COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES
(Unaudited)
(Amount in thousands, except for ratios)



 
 
 
 
 
 
 
 
 
 
 
 
For the Three Months Ended March 31, 2018
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2013
 
2014
 
2015
 
2016
 
2017
 
Earnings:
 
 
 
 
 
 
 
 
 
 
 
 
Income before income taxes
 
$
401,876

 
$
501,272

 
$
530,138

 
$
109,370

 
$
184,527

 
$
2,621

Add: fixed charges
 
24,931

 
39,274

 
27,123

 
18,330

 
20,507

 
3,692

Earnings
 
$
426,807

 
$
540,546

 
$
557,261

 
$
127,700

 
$
205,034

 
$
6,313

Fixed Charges:
 
 
 
 
 
 
 
 
 
 
 
 
Interest expense1
 
$
24,871

 
$
39,211

 
$
27,059

 
$
18,267

 
$
20,221

 
$
3,585

Estimated interest portion of rent expense2
 
60

 
63

 
64

 
63

 
286

 
107

Fixed charges
 
$
24,931

 
$
39,274

 
$
27,123

 
$
18,330

 
$
20,507

 
$
3,692

Ratio of earnings to fixed charges
 
17.12

 
13.76

 
20.55

 
6.97

 
10.00

 
1.71

_____________________________________
1 Interest expense includes amortization of debt discount and expenses.
2 Represents the estimated portion of operating lease rental expense that is considered by us to be representative of interest and amortization of discount related to indebtedness.